← All trials
NCT03351062
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2017
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 844
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Anti-Cancer AssociationLead sponsor
- Chongqing Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Jilin UniversityCollaborator
- Qinghai UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Hebei UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Kunming Medical UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Fudan UniversityOverall official - principal investigator
- Henan Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Central South UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- China Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Shantou UniversityCollaborator
- Hainan People's HospitalCollaborator
- Nanjing Medical UniversityCollaborator
- Nanchang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.